Pressure Biosciences Inc (PBIO)

[stockguard]

Pressure Biosciences (PBIO) Upgraded by ValuEngine to “Buy”

Posted by Lisa Matthews on Feb 5th, 2019
Pressure Biosciences (OTCMKTS:PBIO) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Monday.

Shares of OTCMKTS PBIO traded up $0.37 during trading on Monday, hitting $2.67. The company had a trading volume of 56,278 shares, compared to its average volume of 11,622. Pressure Biosciences has a 12 month low of $1.52 and a 12 month high of $5.00.

Pressure Biosciences (OTCMKTS:PBIO) last posted its quarterly earnings data on Wednesday, November 14th. The company reported ($1.92) EPS for the quarter, missing the consensus estimate of ($0.62) by ($1.30). The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $1.04 million. On average, equities analysts predict that Pressure Biosciences will post -3.29 EPS for the current fiscal year.

Pressure Biosciences Company Profile

Pressure BioSciences, Inc develops pressure cycling technology (PCT) solutions. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources.


https://www.fairfieldcurrent.com/news/2019/02/05/pressure-biosciences-pbio-upgraded-by-valuengine-to-buy.html